Welcome by Morrie Ruffin
Executive Vice President, BIO

• Moderator: Kevin Collins, Shareholder, Corporate/VLG Practice Group, Heller Ehrman LLP
• Jason Bernhard, Global Co-Head Life Sciences Group, Lazard
• Dan Greenleaf, President & CEO, Vioquest Pharmaceuticals
• Tucker Kelly, Principal, Life Sciences Investment Banking, Canaccord Adams
• Zubin Mory, Senior Vice President Investment Banking, Oppenheimer and Co.
• Michael Weiser, MD, PhD, Managing Director, Paramount BioCapital

Merger and acquisition activity was up in 2005 with many large pharmaceutical and biotechnology companies acquiring products and infrastructure. This increasing activity may suggest that for many private companies, M&A is the preferred exit strategy. But what is driving this behavior and what impact will it have on the dynamics of our industry? The panel will address questions surrounding M&A as an exit strategy for private companies, including: What are the important drivers in big pharma's and big biotech's consideration to acquire a private company? How does this influence the way VCs think about and invest in private companies? Should these trends influence the way a biotech CEO builds the business?

• Moderator: Raymond Lin, Partner, Latham & Watkins LLP
• Kenneth I. Moch, President & CEO, Alteon Inc.
• Ting Pau Oei, Partner, L Capital Partners
• Tony Torrington, Ernst & Young

At a time when the U.S. capital markets are generally unreceptive to IPOs by life sciences companies and Sarbanes-Oxley is causing many companies to question the value of going public, U.S. life sciences companies are increasingly turning to the London Stock Exchange's AIM for their IPOs. In addition, U.S. venture capital firms now view IPOs on AIM as a viable exit strategy for their portfolio companies. AIM is not only a more cost-effective alternative to its U.S. counterparts, it is also smaller and more focused than the vast U.S. market, allowing new smaller and mid cap companies to garner far more coverage than they would in the United States. In 2005 alone, 519 companies listed on AIM as compared to 192 (NYSE), 45 (NASDAQ as of 1/06/05), 78 (Euronext), and 55 (Deutsche Boerse). In light of AIM's current momentum in the U.S. marketplace, this workshop is designed to explain the key differences and benefits of AIM for U.S.-based companies as compared to other stock exchanges, using practical case studies and real life examples.

• Moderator: David Vogel, Partner and Head of AIM Practice, Dechert LLP
• John Brady, CEO, Plant Health Care PLC
• David Schulman, Partner and Co-Head of European Life Sciences Practice, Dechert LLP
• Tim Worlledge, Corporate Finance Director, Evolution Securities Limited

IPOs in the biotech sector are off to a strong start in 2006. Of the 10 initial public offerings in the first quarter, 7 were life sciences companies. Some industry insiders predict 30+ IPOs will get out by the end of the year in the US and even more will go out internationally. The trend is a continuation of last year’s performance - nearly half of the 56 venture-backed companies going public last year were biotech companies. But upward trends and open windows don’t guarantee successful transactions. What can you do to be sure your company is poised to take advantage of the current situation? Join us for a lively discussion with a panel of experts as they share their experiences and advice on executing a well timed offering.

• Moderator: Andrew Gilbert, Partner, Emerging Growth, Life Sciences Practice,  Morgan Lewis

What is attracting healthcare venture capital investment today? This panel will discuss the value-from the perspective of several different venture capital groups-of specific business models, partnering agreements, technologies, and exit strategies. A seasoned CEO will also share his experiences in attracting venture investment in several companies. Specific topics covered will include: When is a start-up ready for venture funding? How should a company find and attract venture capitalists? Which kinds of presentations are the most effective? How should a company discuss exit strategy? What is the value of diagnostics vs. devices vs. drugs? How many in-house programs (and types of programs) make sense? When should partnering be considered? Should a company address small or large therapeutic areas? How much management is required for venture investment?

• Moderator: Todd Brady, M.D., Ph.D., Principal, Domain Associates, LLC
• Roger Blevins, Pharm.D., President and Chief Executive Officer, Xsira Pharmaceuticals, Inc.
• Aaron Davidson, M.B.A., Managing Director, H.I.G. Ventures
• Chris Kroeger, M.D., Principal, The Aurora Funds
• Matt Rieke, M.D., Partner, Quaker Bioventures

Because of their scale and cost advantages, virtual biotechs are attracting growing interest.  In theory, any element in the development chain of a biotech company can be outsourced.  In practice, the virtual model represents challenges to both investors and management.  We define "virtual" as a company, for all practical purposes, that outsources every major component of frug development to an outside contractor. What are the advantages and disadvantges of using this business model?

• Moderator: Hal Broderson, M.D., Managing Director, Rock Hill Ventures
• Jay Foust, Director, Research Corporation Technologies, Inc.
• Dennis Goldberg, Ph.D., President and COO, Transport Pharmaceuticals
• Jeffrey Oh, J.D., Senior Vice President, Business Operations, SMART Biosciences

Round table discussion among a diverse group of Life Sciences executives who may offer a truly broad perspective, during which they will respond to questions relating to  strategies for licensing, technology transfer, financing, development and preservation strategies and similar topics relating to preserving, exploiting and developing Intellectual Property in the Life Sciences Industry.

• Moderator: Basam Nabulsi, Partner, McCarter & English, LLP
• Michael Lerner, Esq., Vice President & General Counsel, Reliant Pharmaceuticals, Inc.
• Tracy Warren, General Partner, Battelle Ventures, LP and Innovation Valley Partners, LP
• Bill Wiesler, Ph.D., Associate Director, Office of Cooperative Research  Yale University

Biotechnology  and entrepreneurship have combined to produce unique strategies to generate early stage financing for emerging companies. The panel will provide an update on new opportuniities and challenges in seeking vital pre-seed, first round, and strategic alliance funding sources with representativers from industry, university and medical centers, and venture funders.

• Moderator: Victor Boyajian, National Chair, Venture Capital/Emerging Growth Company Group, Sonnenschein Nath & Rosenthal LLP
• John Cleary  Partner Sonnenschein Venture Technology Group
• James Golubieski, President, The Foundation of the University of Medicine and Dentistry of NJ
• Paddy Mullen  Managing Director, HSS Innovations Hospital for Special Surgery